{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:18:24Z","timestamp":1771258704743,"version":"3.50.1"},"reference-count":126,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Papillary craniopharyngioma (PCP) and adamantinomatous craniopharyngioma (ACP) are distinct, slow-growing tumors of the suprasellar region. Their location, composition, and biology have historically evaded successful surgical radiation and medical therapy. Meanwhile compromise of critical structures either by tumor or treatments increase morbidity, impacting patient and carer quality of life. There has been a paradigm shift in the management of PCP, stemming from the discovery of BRAFV600E mutation in its tumorigenesis. Such a treatment breakthrough may soon be the case for ACP, changing the landscape of craniopharyngioma management. We use a case of ACP partially responding to ERK inhibitor therapy to demonstrate chronicity of disease progression and discuss modern management strategies highlighting the importance of access to tumor agnostic clinical trials, and future directions.<\/jats:p>","DOI":"10.1210\/clinem\/dgae503","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T07:47:37Z","timestamp":1721720857000},"page":"2986-2996","source":"Crossref","is-referenced-by-count":4,"title":["Approach to the Patient: New Era Emerges for Craniopharyngioma Management"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-6980","authenticated-orcid":false,"given":"Annabelle G","family":"Hayes","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, St Vincent's Hospital , Sydney, NSW 2010 ,","place":["Australia"]},{"name":"School of Clinical Medicine, University of New South Wales , Sydney, NSW 2052 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Jonker","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, St Vincent's Hospital , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3716-8611","authenticated-orcid":false,"given":"Christina","family":"Teng","sequence":"additional","affiliation":[{"name":"Drug Development, Scientia Clinical Research , Randwick, NSW 2031 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5399-9431","authenticated-orcid":false,"given":"Charlotte","family":"Lemech","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of New South Wales , Sydney, NSW 2052 ,","place":["Australia"]},{"name":"Drug Development, Scientia Clinical Research , Randwick, NSW 2031 ,","place":["Australia"]},{"name":"Department of Cancer and Haematology, South Eastern Sydney Local Health District , Sydney, NSW 2229 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2273-3753","authenticated-orcid":false,"given":"Andrew J","family":"Killen","sequence":"additional","affiliation":[{"name":"Drug Development, Scientia Clinical Research , Randwick, NSW 2031 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-0523","authenticated-orcid":false,"given":"Hao-Wen","family":"Sim","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of New South Wales , Sydney, NSW 2052 ,","place":["Australia"]},{"name":"Department of Medical Oncology, St Vincent's Hospital , Sydney, NSW 2010 ,","place":["Australia"]},{"name":"Neurooncology, The Kinghorn Cancer Centre , Darlinghurst, NSW 2010 ,","place":["Australia"]},{"name":"Hormones and Cancer Group, Garvan Institute of Medical Research , Darlinghurst, NSW 2010 ,","place":["Australia"]},{"name":"Cooperative Trials Group for Neurooncology, NHMRC Clinical Trials Centre, University of Sydney , Sydney, NSW 2050 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2859-5566","authenticated-orcid":false,"given":"Ann I","family":"McCormack","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, St Vincent's Hospital , Sydney, NSW 2010 ,","place":["Australia"]},{"name":"School of Clinical Medicine, University of New South Wales , Sydney, NSW 2052 ,","place":["Australia"]},{"name":"Hormones and Cancer Group, Garvan Institute of Medical Research , Darlinghurst, NSW 2010 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"issue":"1","key":"2024101600043662600_dgae503-B1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EO-21-0006","article-title":"Epidemiology of craniopharyngiomas: a population-based study in Malta","volume":"1","author":"Craus","year":"2021","journal-title":"Endocr Oncol"},{"issue":"4","key":"2024101600043662600_dgae503-B2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3171\/jns.1998.89.4.0547","article-title":"The descriptive epidemiology of craniopharyngioma","volume":"89","author":"Bunin","year":"1998","journal-title":"J Neurosurg"},{"key":"2024101600043662600_dgae503-B3","first-page":"w14521","article-title":"A ten-year follow-up study of treatment outcome of craniopharyngiomas","volume":"148","author":"Andereggen","year":"2018","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"2024101600043662600_dgae503-B4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12020-022-03134-4","article-title":"Long-term outcomes in patients with adult-onset craniopharyngioma","volume":"78","author":"Dogra","year":"2022","journal-title":"Endocrine"},{"issue":"2","key":"2024101600043662600_dgae503-B5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3171\/jns.1995.83.2.0206","article-title":"Papillary craniopharyngioma: a clinicopathological study of 48 cases","volume":"83","author":"Crotty","year":"1995","journal-title":"J Neurosurg"},{"issue":"4","key":"2024101600043662600_dgae503-B6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11102-021-01127-6","article-title":"Descriptive epidemiology of craniopharyngiomas in the United States","volume":"24","author":"Momin","year":"2021","journal-title":"Pituitary"},{"issue":"2","key":"2024101600043662600_dgae503-B7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Brastianos","year":"2014","journal-title":"Nat Genet"},{"key":"2024101600043662600_dgae503-B8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40478-016-0287-6","article-title":"Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles","volume":"4","author":"H\u00f6lsken","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"2024101600043662600_dgae503-B9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"6","key":"2024101600043662600_dgae503-B10","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/S0002-9440(10)64477-X","article-title":"Craniopharyngiomas of adamantinomatous type harbor \u03b2-catenin gene mutations","volume":"161","author":"Sekine","year":"2002","journal-title":"Am J Pathol"},{"issue":"6","key":"2024101600043662600_dgae503-B11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00401-005-1004-x","article-title":"Common mutations of \u03b2-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region","volume":"109","author":"Buslei","year":"2005","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2024101600043662600_dgae503-B12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00401-014-1270-6","article-title":"BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma","volume":"127","author":"Larkin","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2024101600043662600_dgae503-B13","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s11102-023-01359-8","article-title":"The impact of facility type and volume on treatment and overall survival in craniopharyngioma","volume":"26","author":"Bitner","year":"2023","journal-title":"Pituitary"},{"issue":"2","key":"2024101600043662600_dgae503-B14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/jc.2014-3525","article-title":"Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden","volume":"100","author":"Olsson","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024101600043662600_dgae503-B15","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1210\/clinem\/dgad488","article-title":"Caregiver burden and its relationship to health-related quality of life in craniopharyngioma survivors","volume":"109","author":"Kayadjanian","year":"2023","journal-title":"J Clinical Endocrinol Metab"},{"issue":"5","key":"2024101600043662600_dgae503-B16","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1210\/js.2018-00406","article-title":"Daily sodium monitoring and fluid intake protocol: preventing recurrent hospitalization in adipsic diabetes insipidus","volume":"3","author":"Pabich","year":"2019","journal-title":"J Endocr Soc"},{"issue":"1","key":"2024101600043662600_dgae503-B17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10143-018-0978-5","article-title":"Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review","volume":"43","author":"Coury","year":"2020","journal-title":"Neurosurg Rev"},{"issue":"3","key":"2024101600043662600_dgae503-B18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11060-024-04621-6","article-title":"Fractionated stereotactic radiotherapy in craniopharyngiomas: a systematic review and single arm meta-analysis","volume":"167","author":"Palavani","year":"2024","journal-title":"J Neurooncol"},{"issue":"2","key":"2024101600043662600_dgae503-B19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"N Engl J Med"},{"key":"2024101600043662600_dgae503-B20","doi-asserted-by":"crossref","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","article-title":"Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm","volume":"13","author":"Calvanese","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2024101600043662600_dgae503-B21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1227\/neu.0000000000002346","article-title":"Characteristics and outcomes in pediatric versus adult craniopharyngiomas: a systematic review and meta-analysis","volume":"92","author":"Pang","year":"2023","journal-title":"Neurosurgery"},{"issue":"2","key":"2024101600043662600_dgae503-B22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00381-019-04294-x","article-title":"Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future","volume":"36","author":"Fouda","year":"2020","journal-title":"Childs Nerv Syst"},{"issue":"11","key":"2024101600043662600_dgae503-B23","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.3390\/diagnostics12112745","article-title":"Multidisciplinary management of craniopharyngiomas in children: a single center experience","volume":"12","author":"Del Baldo","year":"2022","journal-title":"Diagnostics"},{"issue":"6","key":"2024101600043662600_dgae503-B24","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/2016.8.FOCUS16268","article-title":"Risk factors associated with the surgical management of craniopharyngiomas in pediatric patients: analysis of 1961 patients from a national registry database","volume":"41","author":"Bakhsheshian","year":"2016","journal-title":"Neurosurg Focus"},{"issue":"Suppl 1","key":"2024101600043662600_dgae503-B25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000120860","article-title":"Craniopharyngioma: results of survey of the American Society of Pediatric Neurosurgery","volume":"21","author":"Sanford","year":"1994","journal-title":"Pediatr Neurosurg"},{"key":"2024101600043662600_dgae503-B26","doi-asserted-by":"crossref","first-page":"1180591","DOI":"10.3389\/fendo.2023.1180591","article-title":"Characteristics and factors influencing hypothalamic pituitary dysfunction in patients with craniopharyngioma","volume":"14","author":"Guo","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2024101600043662600_dgae503-B27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00701-020-04265-1","article-title":"Surgical management of craniopharyngiomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section","volume":"162","author":"Cossu","year":"2020","journal-title":"Acta Neurochir (Wien)"},{"key":"2024101600043662600_dgae503-B28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jocn.2023.10.014","article-title":"Management of first recurrence or progression of craniopharyngioma after resection alone: a systematic review and individual-participant data meta-analysis","volume":"118","author":"Zheng","year":"2023","journal-title":"J Clin Neurosci"},{"issue":"6","key":"2024101600043662600_dgae503-B29","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/jc.2012-3928","article-title":"Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity","volume":"98","author":"Elowe-Gruau","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024101600043662600_dgae503-B30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11102-016-0751-0","article-title":"Risk-adapted, long-term management in childhood-onset craniopharyngioma","volume":"20","author":"M\u00fcller","year":"2017","journal-title":"Pituitary"},{"issue":"1","key":"2024101600043662600_dgae503-B31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12020-015-0683-x","article-title":"Magnetic resonance imaging as predictor of functional outcome in craniopharyngiomas","volume":"51","author":"Mortini","year":"2016","journal-title":"Endocrine"},{"issue":"8","key":"2024101600043662600_dgae503-B32","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/neuonc\/nos142","article-title":"Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program","volume":"14","author":"Zacharia","year":"2012","journal-title":"Neuro Oncol"},{"issue":"4","key":"2024101600043662600_dgae503-B33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/neuros\/nyx570","article-title":"Adult craniopharyngioma: case series, systematic review, and meta-analysis","volume":"83","author":"Dandurand","year":"2018","journal-title":"Neurosurgery"},{"key":"2024101600043662600_dgae503-B34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jss.2018.01.029","article-title":"Comparing survival outcomes of gross total resection and subtotal resection with radiotherapy for craniopharyngioma: a meta-analysis","volume":"226","author":"Wang","year":"2018","journal-title":"J Surg Res"},{"issue":"5","key":"2024101600043662600_dgae503-B35","first-page":"453","article-title":"Comparison of neurocognitive and quality-of-life outcomes in pediatric craniopharyngioma patients treated with partial resection and radiotherapy versus gross-total resection only","volume":"31","author":"Aldave","year":"2023","journal-title":"J Neurosurg Pediatr"},{"issue":"5","key":"2024101600043662600_dgae503-B36","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3171\/2010.11.JNS10670","article-title":"Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series","volume":"114","author":"Mortini","year":"2011","journal-title":"J Neurosurg"},{"issue":"20","key":"2024101600043662600_dgae503-B37","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.3390\/jcm12206551","article-title":"A full view of papillary craniopharyngioma based on expanded endonasal approach: a comprehensive clinical characterization of 101 cases","volume":"12","author":"Jia","year":"2023","journal-title":"J Clin Med"},{"issue":"9","key":"2024101600043662600_dgae503-B38","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.21873\/anticanres.15919","article-title":"Craniopharyngiomas invading the ventricular system: a systematic review","volume":"42","author":"Palmisciano","year":"2022","journal-title":"Anticancer Res"},{"issue":"5","key":"2024101600043662600_dgae503-B39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","article-title":"Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor","volume":"19","author":"Aylwin","year":"2016","journal-title":"Pituitary"},{"issue":"2","key":"2024101600043662600_dgae503-B40","doi-asserted-by":"crossref","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","article-title":"Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy","volume":"108","author":"Brastianos","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2024101600043662600_dgae503-B41","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3171\/2017.11.JNS172373","article-title":"Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report","volume":"130","author":"Himes","year":"2019","journal-title":"J Neurosurg"},{"issue":"17","key":"2024101600043662600_dgae503-B42","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.32197","article-title":"Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations","volume":"125","author":"Juratli","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"2024101600043662600_dgae503-B43","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","article-title":"Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy","volume":"159","author":"Rostami","year":"2017","journal-title":"Acta Neurochir (Wien)"},{"issue":"2","key":"2024101600043662600_dgae503-B44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2217\/cns-2016-0034","article-title":"BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors","volume":"6","author":"Roque","year":"2017","journal-title":"CNS Oncol"},{"issue":"57","key":"2024101600043662600_dgae503-B45","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.18632\/oncotarget.27203","article-title":"Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report","volume":"10","author":"Rao","year":"2019","journal-title":"Oncotarget"},{"issue":"12","key":"2024101600043662600_dgae503-B46","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","article-title":"Successful use of BRAF\/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma","volume":"18","author":"Khaddour","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2024101600043662600_dgae503-B47","first-page":"vdaa141","article-title":"Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma","volume":"2","author":"Di Stefano","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"6","key":"2024101600043662600_dgae503-B48","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3171\/2019.8.JNS19643","article-title":"Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity","volume":"133","author":"Bernstein","year":"2020","journal-title":"J Neurosurg"},{"issue":"1","key":"2024101600043662600_dgae503-B49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3171\/2017.4.JNS163113","article-title":"Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features","volume":"129","author":"Yue","year":"2018","journal-title":"J Neurosurg"},{"issue":"1","key":"2024101600043662600_dgae503-B50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12883-018-1216-z","article-title":"Noninvasive molecular diagnosis of craniopharyngioma with MRI-based radiomics approach","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Neurol"},{"issue":"2","key":"2024101600043662600_dgae503-B51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.33160\/yam.2021.05.002","article-title":"Up-to-date magnetic resonance imaging findings for the diagnosis of hypothalamic and pituitary tumors","volume":"64","author":"Kurosaki","year":"2021","journal-title":"Yonago Acta Med"},{"issue":"1","key":"2024101600043662600_dgae503-B52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3174\/ajnr.A6359","article-title":"Usefulness of contrast-enhanced 3D-FLAIR MR imaging for differentiating rathke cleft cyst from cystic craniopharyngioma","volume":"41","author":"Azuma","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"2024101600043662600_dgae503-B53","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/jmri.27761","article-title":"Machine learning-based multiparametric magnetic resonance imaging radiomic model for discrimination of pathological subtypes of craniopharyngioma","volume":"54","author":"Huang","year":"2021","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"2024101600043662600_dgae503-B54","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11102-023-01339-y","article-title":"Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma","volume":"26","author":"Lin","year":"2023","journal-title":"Pituitary"},{"issue":"2","key":"2024101600043662600_dgae503-B55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11060-020-03432-9","article-title":"Clinical outcomes following proton therapy for adult craniopharyngioma: a single-institution cohort study","volume":"147","author":"Rutenberg","year":"2020","journal-title":"J Neurooncol"},{"key":"2024101600043662600_dgae503-B56","doi-asserted-by":"crossref","first-page":"563","DOI":"10.25259\/SNI_802_2022","article-title":"Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery\/stereotactic radiotherapy or fractionated stereotactic radiotherapy","volume":"13","author":"Kamogawa","year":"2022","journal-title":"Surg Neurol Int"},{"issue":"8","key":"2024101600043662600_dgae503-B57","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/COC.0000000000000378","article-title":"The role of definitive radiotherapy in craniopharyngioma: a SEER analysis","volume":"41","author":"Zhang","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"2024101600043662600_dgae503-B58","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/neuonc\/noac210","article-title":"Proton therapy for adult craniopharyngioma: experience of a single institution in 91 consecutive patients","volume":"25","author":"Beddok","year":"2023","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024101600043662600_dgae503-B59","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ijrobp.2021.02.045","article-title":"Proton radiation therapy for pediatric craniopharyngioma","volume":"110","author":"Jimenez","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2024101600043662600_dgae503-B60","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.3171\/2016.9.FOCUS16298","article-title":"A quantitative analysis of craniopharyngioma cyst expansion during and after radiation therapy and surgical implications","volume":"41","author":"Lamiman","year":"2016","journal-title":"Neurosurg Focus"},{"issue":"10","key":"2024101600043662600_dgae503-B61","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1007\/s00018-021-03798-7","article-title":"Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis","volume":"78","author":"Gonzalez-Meljem","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"2024101600043662600_dgae503-B62","doi-asserted-by":"crossref","first-page":"104905","DOI":"10.1016\/j.ebiom.2023.104905","article-title":"Implications of cellular senescence in paediatric pituitary tumours","volume":"99","author":"Gonzalez-Meljem","year":"2024","journal-title":"EBioMedicine"},{"issue":"8","key":"2024101600043662600_dgae503-B63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/cancers9080103","article-title":"Secondary intracranial tumors following radiotherapy for pituitary adenomas: a systematic review","volume":"9","author":"Yamanaka","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2024101600043662600_dgae503-B64","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1210\/jc.2016-3402","article-title":"Radiotherapy, especially at young age, increases the risk for De Novo brain tumors in patients treated for pituitary\/sellar lesions","volume":"102","author":"Burman","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024101600043662600_dgae503-B65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1470-2045(23)00146-8","article-title":"Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR): a single-arm, phase 2 study","volume":"24","author":"Merchant","year":"2023","journal-title":"Lancet Oncol"},{"key":"2024101600043662600_dgae503-B66","doi-asserted-by":"crossref","first-page":"1180993","DOI":"10.3389\/fonc.2023.1180993","article-title":"Outcome after proton beam therapy versus photon-based radiation therapy in childhood-onset craniopharyngioma patients\u2014results of KRANIOPHARYNGEOM 2007","volume":"13","author":"Friedrich","year":"2023","journal-title":"Front Oncol"},{"issue":"12","key":"2024101600043662600_dgae503-B67","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s11912-023-01471-9","article-title":"Shifting strategies in the treatment of pediatric craniopharyngioma","volume":"25","author":"Gabay","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"2024101600043662600_dgae503-B68","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41598-023-29664-z","article-title":"Molecular biological features of cyst wall of adamantinomatous craniopharyngioma","volume":"13","author":"Zhao","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"2024101600043662600_dgae503-B69","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3171\/2010.1.FOCUS09315","article-title":"Intracystic treatments for craniopharyngioma","volume":"28","author":"Steinbok","year":"2010","journal-title":"Neurosurg Focus"},{"issue":"8-9","key":"2024101600043662600_dgae503-B70","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00381-005-1208-3","article-title":"Long-term outcome and reconsideration of intracystic chemotherapy with bleomycin for craniopharyngioma in children","volume":"21","author":"Takahashi","year":"2005","journal-title":"Childs Nerv Syst"},{"issue":"12","key":"2024101600043662600_dgae503-B71","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00381-001-0524-5","article-title":"Intracystic chemotherapy with bleomycin in the treatment of craniopharyngiomas","volume":"17","author":"Mottolese","year":"2001","journal-title":"Childs Nerv Syst"},{"issue":"6","key":"2024101600043662600_dgae503-B72","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1130-1473(02)70576-9","article-title":"Intratumoural bleomycin as a treatment for recurrent cystic craniopharyngioma. Case report and review of the literature","volume":"13","author":"Al\u00e9n","year":"2002","journal-title":"Neurocirugia (Astur)"},{"issue":"3","key":"2024101600043662600_dgae503-B73","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clineuro.2006.09.002","article-title":"Radiological findings following postsurgical intratumoral bleomycin injection for cystic craniopharyngioma","volume":"109","author":"Kim","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"2024101600043662600_dgae503-B74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/CAD.0b013e328325465e","article-title":"Bleomycin treatment of brain tumors: an evaluation","volume":"20","author":"Linnert","year":"2009","journal-title":"Anticancer Drugs"},{"issue":"4 Suppl","key":"2024101600043662600_dgae503-B75","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3171\/ped.2007.107.4.318","article-title":"Neuroradiological findings of bleomycin leakage in cystic craniopharyngioma. Report of three cases","volume":"107","author":"Lafay-Cousin","year":"2007","journal-title":"J Neurosurg"},{"issue":"1","key":"2024101600043662600_dgae503-B76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/neurosurgery\/46.1.213","article-title":"Fatal toxic effect of bleomycin on brain tissue after intracystic chemotherapy for a craniopharyngioma: case report","volume":"46","author":"Savas","year":"2000","journal-title":"Neurosurgery"},{"key":"2024101600043662600_dgae503-B77","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fendo.2012.00039","article-title":"Intracystic therapies for cystic craniopharyngioma in childhood","volume":"3","author":"Bartels","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2024101600043662600_dgae503-B78","first-page":"CD008890","article-title":"Intracystic bleomycin for cystic craniopharyngiomas in children","volume":"7","author":"Zhang","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2024101600043662600_dgae503-B79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1590\/S0004-282X2011000100011","article-title":"Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon","volume":"69","author":"Dastoli","year":"2011","journal-title":"Arq Neuropsiquiatr"},{"issue":"9","key":"2024101600043662600_dgae503-B80","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00381-007-0409-3","article-title":"Apoptosis in alpha interferon (IFN-\u03b1) intratumoral chemotherapy for cystic craniopharyngiomas","volume":"23","author":"Ierardi","year":"2007","journal-title":"Childs Nerv Syst"},{"issue":"8-9","key":"2024101600043662600_dgae503-B81","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00381-005-1226-1","article-title":"Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma","volume":"21","author":"Cavalheiro","year":"2005","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"2024101600043662600_dgae503-B82","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3171\/2010.1.FOCUS09310","article-title":"Craniopharyngiomas: intratumoral chemotherapy with interferon-\u03b1: a multicenter preliminary study with 60 cases","volume":"28","author":"Cavalheiro","year":"2010","journal-title":"Neurosurg Focus"},{"issue":"2","key":"2024101600043662600_dgae503-B83","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3171\/jns.2000.92.2.0255","article-title":"Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas","volume":"92","author":"Jakacki","year":"2000","journal-title":"J Neurosurg"},{"issue":"6","key":"2024101600043662600_dgae503-B84","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3171\/2012.9.PEDS12225","article-title":"Pegylated interferon-\u03b1-2b for children with recurrent craniopharyngioma","volume":"10","author":"Yeung","year":"2012","journal-title":"J Neurosurg Pediatr"},{"issue":"11","key":"2024101600043662600_dgae503-B85","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/neuonc\/noaa119","article-title":"Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report","volume":"22","author":"Goldman","year":"2020","journal-title":"Neuro Oncol"},{"key":"2024101600043662600_dgae503-B86","author":"Lou"},{"key":"2024101600043662600_dgae503-B87","author":"Brastianos"},{"key":"2024101600043662600_dgae503-B88"},{"issue":"12","key":"2024101600043662600_dgae503-B89","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1210\/jc.2019-01299","article-title":"The medical therapy of craniopharyngiomas: the way ahead","volume":"104","author":"Alexandraki","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024101600043662600_dgae503-B90","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-017-0471-6","article-title":"Wnt\/beta-catenin pathway: modulating anticancer immune response","volume":"10","author":"Pai","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2024101600043662600_dgae503-B91","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/EJE-14-0934","article-title":"Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas","volume":"172","author":"Gomes","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2024101600043662600_dgae503-B92","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/ERC-18-0538","article-title":"SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma","volume":"26","author":"Carreno","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2024101600043662600_dgae503-B93","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ando.2023.10.003","article-title":"First evidence of anti-VEGF efficacy in an adult case of adamantinomatous craniopharyngioma: case report and illustrative review","volume":"84","author":"De Rosa","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"key":"2024101600043662600_dgae503-B94","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3389\/fonc.2019.00791","article-title":"Targeting IL-6 is a potential treatment for primary cystic craniopharyngioma","volume":"9","author":"Grob","year":"2019","journal-title":"Front Oncol"},{"issue":"9","key":"2024101600043662600_dgae503-B95","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnen\/nlx061","article-title":"Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma","volume":"76","author":"Donson","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"key":"2024101600043662600_dgae503-B96","doi-asserted-by":"crossref","first-page":"1225734","DOI":"10.3389\/fendo.2023.1225734","article-title":"Tocilizumab for the fifth progression of cystic childhood craniopharyngioma\u2014a case report","volume":"14","author":"de Vos-Kerkhof","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024101600043662600_dgae503-B97","author":"Dorris"},{"issue":"8","key":"2024101600043662600_dgae503-B98","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/neuonc\/noy035","article-title":"Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma","volume":"20","author":"Coy","year":"2018","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024101600043662600_dgae503-B99","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11060-020-03578-6","article-title":"Immune checkpoint inhibition for pediatric patients with recurrent\/refractory CNS tumors: a single institution experience","volume":"149","author":"Cacciotti","year":"2020","journal-title":"J Neurooncol"},{"issue":"5","key":"2024101600043662600_dgae503-B100","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","article-title":"Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target","volume":"135","author":"Apps","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"3","key":"2024101600043662600_dgae503-B101","doi-asserted-by":"crossref","first-page":"e28753","DOI":"10.1002\/pbc.28753","article-title":"Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma","volume":"68","author":"Patel","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2024101600043662600_dgae503-B102","author":"Dorris"},{"key":"2024101600043662600_dgae503-B103","doi-asserted-by":"crossref","first-page":"775217","DOI":"10.3389\/fphar.2022.775217","article-title":"Characteristics of early phase clinical trials for rare cancers: insights from interviews with stakeholders","volume":"13","author":"Dooms","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"2024101600043662600_dgae503-B104","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/cells10010142","article-title":"The WNT\/ROR pathway in cancer: from signaling to therapeutic intervention","volume":"10","author":"Menck","year":"2021","journal-title":"Cells"},{"key":"2024101600043662600_dgae503-B105","author":"Wang"},{"issue":"4","key":"2024101600043662600_dgae503-B106","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/neuonc\/noac284","article-title":"A promising future for hypothalamic dysfunction in craniopharyngioma","volume":"25","author":"Apps","year":"2023","journal-title":"Neuro Oncol"},{"issue":"11","key":"2024101600043662600_dgae503-B107","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024101600043662600_dgae503-B108","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1210\/jc.2010-0982","article-title":"The diagnosis and management of central hypoadrenalism","volume":"95","author":"Grossman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024101600043662600_dgae503-B109","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1210\/clinem\/dgad003","article-title":"Approach to the patient: preventing adrenal crisis through patient and clinician education","volume":"108","author":"Ahmet","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024101600043662600_dgae503-B110","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024101600043662600_dgae503-B111","doi-asserted-by":"crossref","first-page":"bvad051","DOI":"10.1210\/jendso\/bvad051","article-title":"Managing estrogen therapy in the pituitary patient","volume":"7","author":"Shoung","year":"2023","journal-title":"J Endocr Soc"},{"issue":"5","key":"2024101600043662600_dgae503-B112","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/clinem\/dgaa089","article-title":"Growth hormone therapy does not increase the risk of craniopharyngioma and nonfunctioning pituitary adenoma recurrence","volume":"105","author":"Losa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024101600043662600_dgae503-B113","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1210\/clinem\/dgac517","article-title":"Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort","volume":"107","author":"Maghnie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024101600043662600_dgae503-B114","first-page":"289","article-title":"Arginine or hypertonic saline-stimulated copeptin to diagnose AVP deficiency","volume":"390","author":"Refardt","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2024101600043662600_dgae503-B115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/joim.13261","article-title":"Diagnosis and management of diabetes insipidus for the internist: an update","volume":"290","author":"Christ-Crain","year":"2021","journal-title":"J Intern Med"},{"key":"2024101600043662600_dgae503-B116","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fendo.2019.00630","article-title":"Adipsic diabetes insipidus\u2014the challenging combination of polyuria and adipsia: a case report and review of literature","volume":"10","author":"Dalan","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2024101600043662600_dgae503-B117","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1210\/er.2018-00017","article-title":"Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review","volume":"40","author":"Van Iersel","year":"2019","journal-title":"Endocr Rev"},{"key":"2024101600043662600_dgae503-B118","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-022-00351-z","article-title":"Hypothalamic syndrome","volume":"8","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2024101600043662600_dgae503-B119","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1530\/EJE-17-0044","article-title":"Very long-term sequelae of craniopharyngioma","volume":"176","author":"Wijnen","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2024101600043662600_dgae503-B120","doi-asserted-by":"crossref","first-page":"1256514","DOI":"10.3389\/fendo.2023.1256514","article-title":"Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon","volume":"14","author":"Roth","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2024101600043662600_dgae503-B121","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S2213-8587(24)00087-1","article-title":"Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial","volume":"12","author":"Roth","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2024101600043662600_dgae503-B122","doi-asserted-by":"crossref","first-page":"zsad032","DOI":"10.1093\/sleep\/zsad032","article-title":"Hypersomnia and narcolepsy in 42 adult patients with craniopharyngioma","volume":"46","author":"Dodet","year":"2023","journal-title":"Sleep"},{"issue":"2","key":"2024101600043662600_dgae503-B123","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12020-016-1084-5","article-title":"Oxytocin in survivors of childhood-onset craniopharyngioma","volume":"54","author":"Daubenb\u00fcchel","year":"2016","journal-title":"Endocrine"},{"issue":"5","key":"2024101600043662600_dgae503-B124","doi-asserted-by":"crossref","first-page":"e12842","DOI":"10.1111\/jne.12842","article-title":"Oxytocin release deficit and social cognition in craniopharyngioma patients","volume":"32","author":"Brandi","year":"2020","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"2024101600043662600_dgae503-B125","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2213-8587(23)00120-1","article-title":"Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial","volume":"11","author":"Atila","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024101600043662600_dgae503-B126","doi-asserted-by":"crossref","first-page":"846880","DOI":"10.3389\/fendo.2022.846880","article-title":"Treatment of acquired hypothalamic obesity: now and the future","volume":"13","author":"Dimitri","year":"2022","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae503\/58810018\/dgae503.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae503\/59765626\/dgae503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae503\/59765626\/dgae503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:05:37Z","timestamp":1729037137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/11\/2986\/7718336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":126,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,7,23]]},"published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae503","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,7,23]]}}}